Parotid gland mean dose as a xerostomia predictor in low-dose domains

References

• Setton J, Caria N, Romanyshyn J, et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys. 2012;82:291–298.
   PubMed Web of Science ®Google Scholar
• Peng G, Wang T, Yang KY, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol. 2012;104:286–293.
   PubMed Web of Science ®Google Scholar
• Wijers OB, Levendag PC, Braaksma MMJ, et al. Patients with head and neck cancer cured by radiation therapy: a survey of the dry mouth syndrome in long-term survivors. Head Neck. 2002;24:737–747.
   PubMed Web of Science ®Google Scholar
• Deasy JO, Moiseenko V, Marks L, et al. Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys. 2010;76:S58–S63.
   PubMed Web of Science ®Google Scholar
• Leung SW, Lee TF. Treatment of nasopharyngeal carcinoma by tomotherapy: five-year experience. Radiat Oncol. 2013;8:107.
   PubMed Web of Science ®Google Scholar
• Lee TF, Liou MH, Ting HM, et al. Patient- and therapy-related factors associated with the incidence of xerostomia in nasopharyngeal carcinoma patients receiving parotid-sparing helical tomotherapy. Sci Rep. 2015;5:13165.
   PubMed Web of Science ®Google Scholar
• Braam PM, Terhaard CHJ, Roesink JM, et al. Intensity-modulated radiotherapy significantly reduces xerostomia compared with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:975–980.
   PubMed Web of Science ®Google Scholar
• Dijkema T, Terhaard CHJ, Roesink JM, et al. Large cohort dose-volume response analysis of parotid gland function after radiotherapy: intensity-modulated versus conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:1101–1109.
   PubMed Web of Science ®Google Scholar
• Lyman JT. Complication probability as assessed form dose-volume histograms. Radiat Res. 1985;104:S13–S19.
   Web of Science ®Google Scholar
• Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys. 1989;16:1623–1630.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Common terminology Criteria for Adverse Events (CTCAE) Version 4.03. National Cancer Institute. 2010.
   Google Scholar
• Mohan R. Clinically relevant optimization of 3-D conformal treatments. Med Phys. 1992;19:933–944.
   PubMed Web of Science ®Google Scholar
• Braam PM, Roesink JM, Moerland MA, et al. Long-term parotid gland function after radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:659–664.
   PubMed Web of Science ®Google Scholar
• Mason SJ, Graham NE. Areas beneath the relative operating characteristics (ROC) and relative operating levels (ROL) curves: statistical significance and interpretation. Q J R Meteorol Soc. 2002;128:2145–2166.
   Web of Science ®Google Scholar
• DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–845.
   PubMed Web of Science ®Google Scholar
• Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.
   PubMed Web of Science ®Google Scholar
• Davis J, Goadrich M. The relationship between Precision-Recall and ROC curves. Proceedings of the 23rd international conference on Machine learning; 2006 Jun 25–29; Pittsburgh, PA. New York (NY): ACM; 2006. p. 233–240.
   Google Scholar
• Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011;12:127–136.
   PubMed Web of Science ®Google Scholar
• Miah AB, Gulliford SL, Clark CH, et al. Dose-response analysis of parotid gland function: What is the best measure of xerostomia?. Radiother Oncol. 2013;106:341–345.
   PubMed Web of Science ®Google Scholar
• Lee TF, Fang FM. Quantitative analysis of normal tissue effects in the clinic (QUANTEC) guideline validation using quality of life questionnaire datasets for parotid gland constraints to avoid causing xerostomia during head-and-neck radiotherapy. Radiother Oncol. 2013;106:352–358.
   PubMed Web of Science ®Google Scholar
• Beetz I, Steenbakkers RJHM, Chouvalova O, et al. The QUANTEC criteria for parotid gland dose and their efficacy to prevent moderate to severe patient-rated xerostomia. Acta Oncol. 2014;53:597–604.
   PubMed Web of Science ®Google Scholar
• Beetz I, Schilstra C, Burlage FR, et al. Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: the role of dosimetric and clinical factors. Radiother Oncol. 2012;105:86–93.
   PubMed Web of Science ®Google Scholar
• Meirovitz A, Murdoch-Kinch CA, Schipper M, et al. Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006;66:445–453.
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas AD, Setser A, et al. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007;25:5121–5127.
   PubMed Web of Science ®Google Scholar
• Ho KF, Farnell DJJ, Routledge JA, et al. Comparison of patient-reported late treatment toxicity (LENT-SOMA) with quality of life (EORTC QLQ-C30 and QLQ-H&N35) assessment after head and neck radiotherapy. Radiother Oncol. 2010;97:270–275.
   PubMed Web of Science ®Google Scholar
• Houweling AC, Philippens MEP, Dijkema T, et al. A comparison of dose-response models for the parotid gland in a large group of head-and-neck cancer patients. Int J Radiat Oncol Biol Phys. 2010;76:1259–1265.
   PubMed Web of Science ®Google Scholar
• Buettner F, Miah AB, Gulliford SL, et al. Novel approaches to improve the therapeutic index of head and neck radiotherapy: an analysis of data from the PARSPORT randomised phase III trial. Radiother Oncol. 2012;103:82–87.
   PubMed Web of Science ®Google Scholar
• Dean JA, Wong KH, Gay H, et al. Functional data analysis applied to modeling of severe acute mucositis and dysphagia resulting from head and neck radiation therapy. Int J Radiat Oncol Biol Phys. 2016;96:820–831.
   PubMed Web of Science ®Google Scholar